Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Stopped early · Phase 3

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether polyglutamate paclitaxel is more effective than gemcitabine or vinorelbine in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of gemcitabine or vinorelbine in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Key facts

Study ID

NCT00054197

Run by

CTI BioPharma

Starts

2003-01-01

Expected to finish

2004-10-01

Last updated by the study team

2020-10-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cooper Green Hospital — Birmingham, Alabama, United States
• Medical Oncology/Hematology — Gilroy, California, United States
• Northwest Oncology and Hematology Associates — Coral Springs, Florida, United States
• Midwest Cancer Research Group, Incorporated — Skokie, Illinois, United States
• Medschool Associates North — Reno, Nevada, United States
• New York Oncology Hematology, P.C. - Latham — Latham, New York, United States
• Clinical Research Services — Bismarck, North Dakota, United States
• Charleston Hematology-Oncology, P.A. — Charleston, South Carolina, United States
• Western Washington Medical Group — Everett, Washington, United States
• Western Washington Oncology, Incorporated — Olympia, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.